comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-30 17:44:55 - browse：5

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Oak trusses raised to roof of fire

WSS

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

New warning issued for rebooking air travel after delays, cancellations

NIH fellows want a pay raise. Will that mean less money for grants?

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Iowa House, Senate pass 6

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Sports medicine is finally prioritizing gender equality

'Reaching a detente': STAT's Helen Branswell on covering Covid

Apple is now the first public company to be valued at $3 trillion

The kidney, in all its complexity, is captured in a new atlas

Hepatitis C has a cure — but many Americans still lack access to it

Beach reads and more: STAT's 2023 summer book list

DIEP, the 'gold standard' of breast reconstruction, is under threat

Oak trusses raised to roof of fire

Medical leaders decry Supreme Court decision on affirmative action

Why 40% Americans with Parkinson’s don’t see a neurologist

hotspot

Iowa House, Senate pass 6

New research casts further doubt on a common procedure used with IVF

The kidney, in all its complexity, is captured in a new atlas

Oak trusses raised to roof of fire

Bulgari apologizes to China for listing Taiwan as a country after online backlash

TikTok cracks down on users posting about weight loss drugs

leisure time

hotspot

focus

leisure time